GARD: Genomic Data based Drug Repurposing in Head and Neck Cancer with Large Language Model Validation
Preprint
Abstract
Background/Objectives: Head and neck cancer (HNC) represents the seventh most common cancer diagnosis globally, yet current treatments, including surgery, radiation, and immunotherapy, have shown limited improvement in outcomes. Drug repurposing offers a cost-effective strategy to identify new therapeutic options by leveraging existing medications with known safety profiles. Within this study we developed the GARD pipeline ( G enomic A lteration-based R epurposing for D rugs), designed to uncover repurposing candidates for HNC using genomic and network-based approaches. Methods: GARD integrates multi-omics data from The Cancer Genome Atlas (TCGA), including copy number variation (CNV) and somatic mutations (SOM). The cohort was stratified by human papillomavirus (HPV) status. Risk-associated genes were identified and then expanded via high-confidence protein–protein interaction (PPI) networks. Top candidate genes were filtered through comprehensive analysis of publicly available literature data in PubMed using LLM to validate the relationship between the identified genes and HNC. The validated top risk genes and their network-expanded neighbors were mapped against DrugBank, and through statistical significance testing, established significant drug-gene associations. Results: Significant genes associated with HNC, inferred by genomics alteration, were identified across HPV-positive and HPV-negative subgroups, such as PIK3CA, SOX2, TP53, EIF4G1, TLR7, CLDN1, PRKCI, and EPHA2. Further expansion through the PPI network identified other targetable genes such as EGFR, ERBB2, and the FGFRs. Literature based validation efforts ensured provided confidence in the gene-disease association. Drug-gene mapping revealed candidates spanning already in clinical trials for HNC (e.g. Afatinib, Cabozantinib, Dasatinib, Brigatinib, Lenvatinib, Capivasertib, Erdafitinib) and emerging or repurposing candidates (Amuvatinib, XL765 (Voxtalisib), Golotimod, Artenimol, Quercetin, and Acetylsalicylic Acid), offering opportunities for precision repurposing. Conclusions: The GARD pipeline demonstrates a genomics-driven, network-informed framework for systematic drug repurposing in HNC. HPV stratification enhances precision, literature-based validation strengthens confidence, and integrated drug mapping enables refinement of existing therapies and discovery of novel candidates for personalized treatment strategies. Code Availability: The full implementation of the GARD pipeline, including preprocessing scripts, statistical analysis modules, and visualization tools, is publicly available on GitHub at: https://github.com/pvtanike/Genomic-Landscape-Based-Drug-Repurposing.git Simple Summary: Head and neck cancer (HNC) is among the most prevalent and challenging cancers world-wide. Developing new drugs is expensive and time-consuming, so this study explored a faster, cost-effective approach utilizing existing medications with established safety profiles: drug repurposing. We developed the GARD pipeline ( G enomic A lteration-based R epurposing for D rugs), which utilizes large-scale genomic data from The Cancer Genome Atlas (TCGA) to identify key genomics changes in HNC. These genes are expanded through protein–protein interaction networks to capture related pathways and then validated using evidence from thousands of PubMed articles extracted by large language model (LLM) tools. Finally, validated genes are matched with drugs using the DrugBank database. This approach uncovered both known cancer drugs and promising new candidates. These included targeted therapies such as Fostamatinib, Nintedanib, Brigatinib, Regorafenib, and Lenvatinib, as well as emerging compounds like Artenimol, Quercetin, and Acetylsalicylic Acid (Aspirin). Through a combination of genomic analysis, network expansion, and literature validation, the GARD pipeline offers a powerful way to accelerate personalized cancer treatments while reducing cost and development time.Keywords
All Related Versions
- Published version: Cancers, 18 (5), 757.
Funding Information
- NIH/NCI (U54CA302426)
- NIH/NIAID (P0AI178377)
This publication has 86 references indexed in Scilit:
- The ERBB Family of Receptor Tyrosine Kinases: Key Players in Cancer2025
- Buparlisib and Paclitaxel in Patients with Head and Neck Squamous Cell Carcinoma: Immunogenomic Biomarkers of Efficacy from the BERIL-1 StudyTargeted Oncology, 2025
- Knockdown of RFC 4 inhibits cell proliferation of oral squamous cell carcinoma in vitro and in vivoFEBS Open Bio, 2024
- Targeting tumor cells with pyrazolo[3,4-d]pyrimidine scaffold: A literature review on synthetic approaches, structure activity relationship, structural and target-based mechanismsArabian Journal of Chemistry, 2022
- Inhibition of JAK2/STAT3 reduces tumor‐induced angiogenesis and myeloid‐derived suppressor cells in head and neck cancerMolecular Carcinogenesis, 2017
- Copanlisib: First Global ApprovalDrugs, 2017
- A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomasCancer Chemotherapy and Pharmacology, 2013
- Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinomaCancer, 2010
- EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinomaInternational Journal of Cancer, 2002
- The CDKN2A (p16) Gene and Human CancerMolecular Medicine, 1997